European Commission approves Rytelo for LR- MDS-related anaemia
The European marketing authorisation offers a new treatment option for…
The European marketing authorisation offers a new treatment option for patients with transfusion-dependent anaemia in lower-risk myelodysplastic syndromes (LR-MDS), who are unresponsive to erythropoiesis-stimulating agents.